ObsEva Annual Report 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published its Annual Report 2022 to Shareholders.
Related news for (OBSV)
- ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
- ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
- ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
- ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares